Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...
Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...
La La Anthony is partnering with Amgen to raise awareness and support those struggling with plaque psoriasis. The ...
Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, ...
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...
Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...
First for Women on MSN5d
La La Anthony on Her Plaque Psoriasis: ‘It Doesn't Have To Hold You Back'Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the ...
UCB, a global biopharmaceutical company, today announced further long-term data from the Phase 3 trials, and their open-label extensions, investigating BIMZELX® (bimekizumab-bkzx) in adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback